Search Result

Results for "

cannabinoid receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cannabinoid Receptor (200) 5-HT Receptor (1) Akt (2) Aldehyde Dehydrogenase (ALDH) (1) Androgen Receptor (1) ANGPTL (1) Apoptosis (4) Arrestin (1) Autophagy (15) Bacterial (6) Biochemical Assay Reagents (2) Caspase (2) CETP (1) Cholinesterase (ChE) (2) Cytochrome P450 (5) DAGL (2) Dopamine Receptor (1) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (2) EGFR (1) Endogenous Metabolite (29) Environmental Pollutants (2) FAAH (3) Fatty Acid Synthase (FASN) (1) Ferroptosis (1) Fungal (2) GPR55 (4) Heme Oxygenase (HO) (1) HIF/HIF Prolyl-Hydroxylase (2) Interleukin Related (3) Isotope-Labeled Compounds (14) Keap1-Nrf2 (1) Lipoxygenase (1) MAGL (1) MHC (1) mTOR (2) NF-κB (4) NO Synthase (3) P-glycoprotein (1) p38 MAPK (2) PDK-1 (1) PERK (2) PI3K (2) Potassium Channel (1) PPAR (2) Reactive Oxygen Species (ROS) (1) Reference Standards (12) Serotonin Transporter (1) Sigma Receptor (1) Tau Protein (2) TNF Receptor (2) TRP Channel (18) VEGFR (2) α-synuclein (1)
By Research Areas:	Cancer (23) Cardiovascular Disease (6) Endocrinology (2) Infection (8) Inflammation/Immunology (43) Metabolic Disease (48) Neurological Disease (128)
Click Chemistry:	Azide (1)

221

Inhibitors & Agonists

Bibliothèques de criblage

Biochemical Assay Reagents

Peptides

Natural
Products

Protéines recombinantes

Isotope-Labeled Compounds

Antibodies

Click Chemistry

AM251 Maximum Cited Publications 23 Publications Verification	Cannabinoid Receptor	Neurological Disease
AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC₅₀ of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC₅₀ of 39 nM .

Monlunabant 1 Publications Verification (S)-MRI-1891; INV-202	Cannabinoid Receptor Arrestin	Metabolic Disease
Monlunabant ((S)-MRI-1891) is an orally active antagonist for cannabinoid receptor 1 (CB1), binds to hCB1 and hCB2 with K_i of 0.3 nM and 613 nM .

Synaptamide 1 Publications Verification N-Docosahexaenoyl ethanolamine (DHEA); Docosahexaenoyl ethanolamide	Cannabinoid Receptor	Neurological Disease
Synaptamide (Dehydroepiandrosteron; DHEA) is an endogenous metabolite and structural analogue of Anandamide. Synaptamide binds to both the cannabinoid-1 and 2 (CB1 and CB2) cannabinoid receptors and has anti-inflammatory properties. Synaptamide is the first small-molecule endogenous ligand of an adhesion G protein-coupled receptor (aGPCR) .

Yangonin 1 Publications Verification	Cannabinoid Receptor NF-κB Autophagy	Inflammation/Immunology
Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a K_i of 1.79 μM and 0.72 μM, respectively.

JTE-907	Cannabinoid Receptor TRP Channel Interleukin Related ANGPTL VEGFR	Metabolic Disease Inflammation/Immunology
JTE-907 is a selective and orally active cannabinoid CB2 receptor inverse agonist and exerts anti-inflammatory effects. JTE-907 upregulates IL-6, MCP-1, IL-1β, VEGF, ANGPTL4, and TRPV1 in mature adipocytes. JTE-907 downregulates CB1, MCP-1, and IL-1β in preadipocytes. JTE-907 inhibits ear swelling in mice. JTE-907 reverses the protective effects of CB2 agonists and Anandamide (HY-10863) against cytokine-evoked colonic mucosal damage. JTE-907 can be used for the research of allergic dermatitis, obesity, and colitis .

Otenabant 2 Publications Verification CP-945598	Cannabinoid Receptor	Metabolic Disease
Otenabant is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

Taranabant 2 Publications Verification MK-0364	Cannabinoid Receptor	Metabolic Disease
Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding K_i of 0.13 nM for the human CB1R in vitro.

CB1 antagonist 2 AM4113	Cannabinoid Receptor	Neurological Disease Metabolic Disease
CB1 antagonist 2 (AM4113) is an orally active cannabinoid receptor type 1 (CB1R) antagonist. CB1 antagonist 2 suppresses appetite, reduces body weight, and blocks addictive behaviors such as heroin addiction, without causing adverse effects like nausea and depression that are associated with traditional CB1 inverse agonists. CB1 antagonist 2 can be used in studies related to obesity and opioid addiction .

Leelamine	Environmental Pollutants Cannabinoid Receptor PDK-1	Metabolic Disease Cancer
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC₅₀ value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .

(±)-Ibipinabant 1 Publications Verification (±)-SLV319; (±)-BMS-646256	Cannabinoid Receptor	Metabolic Disease
(±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC₅₀ of 22 nM.

AM-6538	Cannabinoid Receptor	Neurological Disease
AM6538 is a long-acting, high affinity and pseudo-irreversible cannabinoid (CB) antagonist. AM6538 is a structural analog of rimonabant. AM6538 can be effectively used to evaluate the apparent efficacy of cannabinoid full and partial agonists. AM6538 may be useful in future studies that require temporary reductions in cannabinoid receptor availability . AM-6538 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Olorinab 2 Publications Verification APD 371	Cannabinoid Receptor	Neurological Disease
Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB₂) agonist, with an EC₅₀ of 6.2 nM for hCB₂.

GW842166X	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GW842166X is a potent and selective cannabinoid receptor 2 (CB2) agonist with IC₅₀ values of 63 and 91 nM for human and rat CB2, respectively.

VSN-16	Cannabinoid Receptor	Cardiovascular Disease Inflammation/Immunology
VSN-16 is a **cannabinoid receptor** agonist with vasodilatory activity. VSN-16 can be used for the study of multiple sclerosis .

GP1a	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization .

Taranabant racemate MK-0364 racemate	Cannabinoid Receptor	Neurological Disease
Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the *Cannabinoid-1* (CB1) *receptor* extracted from patent WO 2004048317 A1 .

Dihomo-γ-Linolenoyl Ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively .

CB2 receptor agonist 2	Cannabinoid Receptor	Neurological Disease
CB2 receptor agonist 2 is a potent and selective agonist for the CB2 (cannabinoid type 2) receptor with a K_i of 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for CB2 .

NESS 0327 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
NESS 0327 is a *cannabinoid* antagonist with high selectivity for the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor .

Auriculasin	VEGFR Ferroptosis PI3K Akt mTOR Cannabinoid Receptor p38 MAPK	Neurological Disease
Auriculasin is an anticancer agent that inhibits VEGFR2, PI3K/AKT/mTOR, MAPK. Auriculasin can inhibit cell proliferation, induce cell apoptosis, and inhibit angiogenesis, and promotes mitochondrial oxidative stress and ferroptosis. Auriculasin is also active at the **cannabinoid receptor CB1 with an IC₅₀** of 8.92 μM. Auriculasin can be used in cancer research, especially related diseases such as prostate cancer and non-small cell lung cancer, as well as research on the development of anti-angiogenic drugs .

AM11542	Cannabinoid Receptor	Metabolic Disease
AM11542 is a cannabinoid receptor 1 (CB1) agonist with a human CB1 K_i of 0.11 nM. AM11542 stabilizes the active conformational state of the CB1 receptor. AM11542 can be used for the research of obesity .

BPRCB1184 CB1-IN-1	Cannabinoid Receptor	Metabolic Disease
BPRCB1184 is a peripherally restricted 1-type cannabinoid receptor (CB1) antagonist, whose activity is associated with the regulation of obesity-related endocannabinoid system. BPRCB1184 regulates the activity of the endocannabinoid system, promotes lipid mobilization, reduces triglyceride storage, improves glucose metabolism, decreases food intake and body weight, while enhances insulin resistance and improves blood lipid levels. BPRCB1184 can be used in obesity-related research .

Arachidonylcyclopropylamide 2 Publications Verification ACPA	Cannabinoid Receptor	Neurological Disease
Arachidonylcyclopropylamide (ACPA) is a potent and selective CB1 receptors agonist. Arachidonylcyclopropylamide inhibits forskolin-stimulated cAMP production in CHO cells transfected with human cannabinoid CB1 receptors (IC₅₀=2 nM) .

CB1/2 agonist 3	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a CB1/CB2 (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with K_i values of 5.9 nM and 3.5 nM, respectively .

zr17-2	Keap1-Nrf2 Heme Oxygenase (HO)	Cardiovascular Disease Neurological Disease
zr17-2 is a cold inducible RNA-binding protein (CIRBP) agonist. zr17-2 has anti-inflammatory and anti-oxidant and can be used for the study of myocardial infarction. zr17-2 is a hypothermia mimetic molecule that reduces oxidative stress-induced retinal cell death .

LEI-101	Cannabinoid Receptor	Neurological Disease
LEI-101 is a potent, selective, and orally bioavailable **cannabinoid CB2 receptor** agonist, with a pEC₅₀ of 8 for hCB2, and a pK_i of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors .

CB2R/FAAH modulator-1	Cannabinoid Receptor FAAH	Inflammation/Immunology
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with K_is of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .

Arachidonoyl ethanolamide phosphate	Cannabinoid Receptor Apoptosis	Neurological Disease
Arachidonoyl ethanolamide phosphate, an endocannabinoid, is an endogenous ligand for cannabinoid receptors in the central nervous system (CB1 subtype) and peripheral immune cells (CB2 subtype) .

CB2R ligand-1	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology Cancer
CB2R ligand-1 (Compound L14) is a selective Cannabinoid type 2 receptor (CB2R) ligand with a with K_i of 0.16  nM for CB2R over CB1R. CB2R ligand-1 as be used as a tracer for positron emission tomography (PET) imaging of neurodegenerative diseases, inflammation and cancer .

Neuroprotective agent 15	Cholinesterase (ChE) Cannabinoid Receptor Aldehyde Dehydrogenase (ALDH) Caspase Apoptosis	Neurological Disease
Neuroprotective agent 15 (Compound 3e) is a neuroprotective agent. Neuroprotective agent 15 is a selective butyrylcholinesterase (BChE) inhibitor, with IC₅₀ values of 2.6 and 114.3 μM for BChE and AChE respectively. Neuroprotective agent 15 has cannabinoid CB2 receptor (CB2 receptor) agonistic activity. Neuroprotective agent 15 can reduce cell death, LDH release and Caspase-3/7 activity, and inhibit apoptosis. Neuroprotective agent 15 can reduce the formation of superoxide free radicals, maintain cell morphology, and significantly lower oxidative stress levels. Neuroprotective agent 15 can be used in the research of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease .

1'-Naphthoyl-2-methylindole	Cannabinoid Receptor	Neurological Disease
1'-Naphthoyl-2-methylindole (Compound 88) is a cannabinoid mimetics and an inhibitor for Win 55212-2, that inhibits 34% of ^[3H]Win 55212-2 binding to cannabinoid receptors at 3 μM .

Otenabant Hydrochloride CP 945598 Hydrochloride	Cannabinoid Receptor	Metabolic Disease
Otenabant Hydrochloride is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

Noladin ether	Cannabinoid Receptor	Neurological Disease
Noladin ether is a potent and selective agonist of **cannabinoid CB₁ receptor, with a K_i** of 21.2 nM. Noladin ether can cause hypothermia, intestinal immobility, and mild antinociception .

Rosonabant	Cannabinoid Receptor	Cardiovascular Disease Metabolic Disease
Rosonabant is a selective antagonist for **cannabinoid receptor** (CB1 receptor), which reduces body weight and improves improves the risk of obesity-related cardiovascular metabolic diseases. Rosonabant exhibits adverse side effect, such as nausea and mental disorder .

SER-601	Cannabinoid Receptor	Neurological Disease
SER-601 is a potent and selective peripheral cannabinoid (CB2) receptor agonist with a K_i of 6.3 nM. SER-601 has analgesic and antidiabetic properties and can be used for relevant research .

Virodhamine hydrochloride	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine (hydrochloride) is a cannabinoid CB1 receptor partial agonist and cannabinoid CB2 receptor full agonist .

Tocrifluor 1117 T1117	GPR55 Cannabinoid Receptor	Cardiovascular Disease
Tocrifluor 1117 (T1117), a fluorescent form of the cannabinoid CB1 receptor antagonist AM251 (HY-15443), is a selective fluorescent GPR55 ligand. Tocrifluor 1117 is a potent tool for identifying the cellular location of cannabinoid receptors (including GPR55 in living tissues) (Ex/Em=543/590 nm) .

O-2050	Cannabinoid Receptor	Neurological Disease
O-2050 is a high affinity **cannabinoid CB₁ receptor antagonist with a K_i** of 2.5 nM. O-2050 inhibits cannabinoid CB₂ receptor (K_i=0.2 nM). O-2050 can cause locomotor stimulation in mice .

Amauromine	Cannabinoid Receptor	Neurological Disease
Amauromine is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist with K_i and K_b values of 178 nM and 66.6 nM, respectively .

GAT211	Cannabinoid Receptor	Neurological Disease
GAT211 is a cannabinoid 1 receptor (CB1R) positive allosteric modulator (PAM). GAT211 activates cAMP and β-arrestin2 with EC₅₀ values of 260 nM and 650 nM, respectively. GAT211 inhibits GAT211 can be used for neuropathic and/or inflammatory pain research .

(±)5(6)-EET Ethanolamide	Cannabinoid Receptor Cytochrome P450	Neurological Disease Inflammation/Immunology
(±)5(6)-EET Ethanolamide is a metabolite of Anandamide (HY-10863) generated via oxidation by cytochrome P450 enzymes. (±)5(6)-EET Ethanolamide is also a selective cannabinoid receptor 2 (CB2) agonist. (±)5(6)-EET Ethanolamide has K_i values of 11.4 μM and 8.9 nM for human CB1 and CB2, respectively . (±)5(6)-EET Ethanolamide can be used in research on immunomodulation and neuroinflammation .

CB2R agonist 4	Cannabinoid Receptor Apoptosis Reactive Oxygen Species (ROS)	Cancer
CB2R agonist 4 is a cannabinoid receptor 2 (CB2R) agonist with an EC₅₀ value of 6.9 μM. CB2R agonist 4 can induce cell apoptosis, ROS production and protein misfolding. CB2R agonist 4 shows cytotoxicity to a panel of tumor cell lines. CB2R agonist 4 can be used for the research of cancer .

JHU-75528	Cannabinoid Receptor	Neurological Disease
JHU-75528 is a novel ligand of the cannabinoid receptor (CB1). JHU-75528 can be used in the research of imaging CB1 receptor .

CB1R antagonist 1	Cannabinoid Receptor	Metabolic Disease
CB1R Allosteric modulator 5, a selective cannabinoid-1 receptor (CB1R) inverse agonist with an IC₅₀ value of 4.2 μM and EC₅₀ value of ＞10 μM. CB1R Allosteric modulator 5 can be used for the research of metabolic and obesity .

MDA7	Cannabinoid Receptor	Neurological Disease
MDA7 is the selective agonist for cannabinoid receptor 2 with EC₅₀ of 128 nM and 67.4 nM in human CB2 receptor and rat CB2 receptor. MDA7 exhibits good affinity to human CB2 receptor and rat CB2 receptor with K_i of 422 nM and 238 nM. MDA7 exhibits analgesic activity in rats models .

AB-FUBINACA 3-fluorobenzyl isomer	Cannabinoid Receptor	Neurological Disease
AB-FUBINACA 3-fluorobenzyl isomer is a synthetic *cannabinoid* that belongs to the indole derivatives and has a high affinity for the central CB1 receptors (K_i= 0.9 nM), exhibiting anticonvulsant activity .

Cat. No.	Nom du produit

HY-L006

GPCR/G Protein Compound Library

3,422 compounds

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers the production of any number of second messengers. GPCRs play an important role in the human body, and increased understanding of these receptors has greatly affected modern medicine. In fact, researchers estimate that between one-third to one-half of all approved drugs act by binding to GPCRs. GPCRs are a large group of drug targets in drug discovery.

MCE provides a unique collection of 3,422 small molecules targeting GPCRs that can be used in the screening for various GPCRs-related research and drug development projects.

Cat. No.	Nom du produit	Type

HY-110004

ACEA Arachidonyl-2-chloroethylamide	Biochemical Assay Reagents
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory .

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine

Biochemical Assay Reagents

Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

Cat. No.	Nom du produit	Target	Research Area

HY-P1091

Hemopressin (human, mouse)	Cannabinoid Receptor	Neurological Disease
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models .

HY-P1090

Hemopressin(rat)	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models .

HY-P1397

RVD-Hpα	Cannabinoid Receptor	Neurological Disease
RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a CB1 cannabinoid receptor agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2 .

HY-P1091A

Hemopressin(human, mouse) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models .

HY-P1090A

Hemopressin(rat) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models .

HY-P11831

RD-pepcan-11	Cannabinoid Receptor PERK	Inflammation/Immunology
RD-pepcan-11 is a CB1 receptor agonist. RD-pepcan-11 increases the relative phosphorylation level of ERK1/2. RD-pepcan-11 mediates analgesic effects through interaction with CB1 receptors in a carrageenan-induced mouse inflammatory pain model. RD-pepcan-11 can be used in studies related to inflammatory pain .

Recombinant Proteins Recommended:

Cannabinoid Receptor

Species:	Human (5)
Tag:	His (3) Tag Free (2)
Source:	HEK293 (4) E. coli Cell-free (1)

Cat. No.	Compare	Nom du produit	Species	Source	Image

HY-P700636

	CNR2 Protein-VLP, Human (HEK293) CNR2; cannabinoid receptor 2 (macrophage); cannabinoid receptor 2; CB2	Human	HEK293
	CNR2 Protein-VLP, Human (HEK293) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P702775. May have binding signals with Anti-His antibodies.

HY-P702793

	CNR2 Protein-VLP, Human (HEK293, His) CNR2; cannabinoid receptor 2 (macrophage); cannabinoid receptor 2; CB2	Human	HEK293
	CNR2 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

HY-P700408

	CNR1 Protein-VLP, Human (HEK293, His) cannabinoid receptor 1 (brain); CNR; cannabinoid receptor 1; CANN6; CB R; CB1; CB1A; CB1K5; central cannabinoid receptor; CB-R; CB1R;	Human	HEK293
	CNR1 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

HY-P704544

	CNR1 Protein-VLP, Human (T210A, HEK293) cannabinoid receptor 1 (brain); CNR; cannabinoid receptor 1; CANN6; CB R; CB1; CB1A; CB1K5; central cannabinoid receptor; CB-R; CB1R;	Human	HEK293
	CNR1 Protein-VLP, Human (T210A, HEK293) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

HY-P702255

	CNR2 Protein, Human (Cell-Free, His) cannabinoid receptor 2; CX5; CB-2; CB2	Human	E. coli Cell-free
	CNR2 Protein, a heterotrimeric G protein-coupled receptor, crucially inhibits adenylate cyclase, mediating functions in inflammatory responses, nociceptive transmission, and bone homeostasis. Its modulation of cellular signaling underscores its significance in physiological processes, positioning CNR2 Protein as a key regulator in inflammatory, sensory mechanisms, and bone equilibrium. CNR2 Protein, Human (Cell-Free, His) is the recombinant human-derived CNR2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Ajouter au chariot Obtenir un devis

Cat. No.	Nom du produit	Chemical Structure

HY-10863S

Anandamide-d8

Anandamide-d8 is a deuterated labeled Anandamide . Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-14136S

Rimonabant-d10
Rimonabant-d₁₀ is deuterium labeled Rimonabant. Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-113421S

Linoleoyl ethanolamide-d4

Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide . Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

HY-B0151S2

Pregnenolone-d4-1

Pregnenolone-d₄-1 is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication . Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels .

HY-14137S

Rimonabant-d10 hydrochloride
Rimonabant-d₁₀ (hydrochloride) is the deuterium labeled Rimonabant hydrochloride. Rimonabant hydrochloride (SR 141716A hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an K_i of 1.8 nM. Rimonabant hHydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3) .

HY-110189S1

Pregnenolone monosulfate-d4 sodium

Pregnenolone monosulfate-d₄ sodium is the deuterium labeled Pregnenolone monosulfate sodium (HY-110189) . Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium can protect the brain from cannabis intoxication . Pregnenolone monosulfate sodium is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels .

HY-B0151S

Pregnenolone-d4

Pregnenolone-d₄ is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication . Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels .

HY-B0151S1

Pregnenolone-13C2,d2

Pregnenolone- ¹³C₂,d₂ is the deuterium and ¹³C labeled Pregnenolone (HY-B0151). Pregnenolone is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels .

HY-W705168

Yangonin-d3
Yangonin-d₃ is the deuterium labeled Yangonin (HY-N0919). Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a Ki of 1.79 μM and 0.72 μM, respectively.

HY-10863S1

Anandamide-d11
Anandamide-d₁₁ is deuterium labeled Anandamide. Anandamide is an immune modulator in the central nervous system acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55) .

HY-W008364S1

Olivetol-d9
Olivetol-d₉ is the deuterium labeled Olivetol. Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2[3]. Olivetol also inhibits CYP2C19 and CYP2D6 activities.

HY-W770198

2-Linoleoyl glycerol-d5

2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

HY-124089S

Eicosapentaenoyl ethanolamide-d4

Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant .

HY-110189S

Pregnenolone monosulfate sodium-13C2,d2

Pregnenolone monosulfate (sodium)- ¹³C₂,d₂ is the ¹³C- and deuterium labeled Pregnenolone monosulfate sodium. Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium salt acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium salt can protect the brain from cannabis intoxication . Pregnenolone monosulfate sodium salt is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels .

HY-B0151S3

Pregnenolone-d6

Pregnenolone-d₆ (3β-Hydroxy-5-pregnen-20-one-d₆) is the deuterium labeled Pregnenolone (HY-B0151) . Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication . Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels .

Host:	Mouse (1) Rabbit (4)
Reactivity:	Human (4) Mouse (1) Rat (2) human (1)
Application:	IHC-P (2) ICC/IF (2) IF-Tissue (1) IP (1) IHC-F (1) WB (5) ELISA (2)
Isotype:	IgG (4) IgG1 (1)
Conjugation:	Non-conjugated (5)
Clonality:	Polyclonal (1) Monoclonal (2) Recombinant (2)
Modification:	Phosphorylated (1) Unmodified (2)

Cat. No.	Compare	Nom du produit	Application	Reactivity	Image

HY-P81627

	Cannabinoid Receptor I Antibody CNR1; CNR; cannabinoid receptor 1; CB-R; CB1; CANN6	WB, IHC-P, IHC-F, ICC/IF, ELISA	Human, Rat
	Cannabinoid Receptor I Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Cannabinoid Receptor I.

HY-P82605

	*Phospho-Cannabinoid* Receptor I (Ser316) Antibody (YA2350)** CNR1; CNR; cannabinoid receptor 1; CB-R; CB1; CANN6	WB	Human
	Phospho-Cannabinoid Receptor I (Ser316) Antibody (YA2350) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Cannabinoid Receptor I (Ser316).

HY-P89397

	Cannabinoid Receptor I Antibody (YA8850) CNR1; CNR; cannabinoid receptor 1; CB-R; CB1; CANN6; CB1R antibody	WB, IHC-P	Human, Mouse, Rat
	Cannabinoid Receptor I Antibody is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cannabinoid Receptor I.

HY-P82605A

	*Phospho-Cannabinoid* Receptor I (Ser316) Antibody (YA2350)(PBS only)** CNR1; CNR; cannabinoid receptor 1; CB-R; CB1; CANN6	WB	Human
	Phospho-Cannabinoid Receptor I (Ser316) Antibody (YA2350) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Cannabinoid Receptor I (Ser316).

HY-P89774

	*CB2/Cannabinoid* Receptor 2/CNR2 Antibody (YA9118)**	WB, ICC/IF, IF-Tissue, IP, ELISA	human
	CB2/Cannabinoid Receptor 2/CNR2 Antibody (YA9118) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CB2/Cannabinoid Receptor 2/CNR2.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Ajouter au chariot Obtenir un devis

Cat. No.	Nom du produit		Classification

HY-155481

CB2 receptor antagonist 3		Azide
CB2 receptor antagonist 3 (compound (S)-1) is an inverse agonist of the cannabinoid receptor CB2R with Kd=39 nM. CB2 receptor antagonist 3 can be used as a tool to synthesize a variety of CB2R probes .

Demande en ligne

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Civilité			Country or Region *
Nom du demandeur *			Nom de l'organisation *
Department *
Adresse e-mail *			Nom du produit *
Cat. No.			Requested quantity *
Numéro de téléphone *
Remarques

Demande en ligne

Inquiry Information

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

cannabinoid receptor

Inhibitors & Agonists

Bibliothèques de criblage

Biochemical Assay Reagents

Peptides

NaturalProducts

Protéines recombinantes

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products